Mori Keiichiro
assistant professor
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (4)
Objective To assess cure fraction and conditional survival probabilities for oncological outcomes in patients with T1 high‐grade (T1HG) non‐muscle‐invasive bladder carcinoma (NMIBC) treated with adequate Bacillus Calmette‐Guérin (BCG) immunotherapy. Patients and Methods This multi‐institutional retrospective cohort study included 1403 patients with T1HG NMIBC treated between 2007 and 2020, adhering to modern guidelines including mandatory second transurethral resection of bladder tumour and adequate BCG, defined as at least five of six induction doses and at least two of three maintenance doses. Cure fraction, defined as the proportion of patients who will never experience the event of interest, was calculated for recurrence‐free survival (RFS), progression‐free survival (PFS), cancer‐specific survival (CSS) and overall survival (OS) using a mixture cure model. Conditional survival probabilities over 5 years were also computed. Results Cure fractions were 41% (95% confidence interval [CI] 36%–46%) for RFS, 71% (95% CI 65%–76%) for PFS, 76% (95% CI 70%–83%) for CSS, and 38% (95% CI 28%–49%) for OS. Patients in very‐high‐risk subgroups, according to the European Association of Urology risk stratification, showed significantly lower cure fractions, particularly for PFS (61% [95% CI 50%–72%]) and CSS (59% [95% CI 34–84%]). Conditional survival analysis demonstrated that patient prognoses improved over time, with 5‐year conditional RFS, PFS, CSS and OS probabilities exceeding 90% for patients who were event‐free at 5 years from diagnosis. Conclusions We found that BCG immunotherapy achieves a statistical cure in select T1HG NMIBC patients, with avoidance of progression to muscle‐invasive bladder carcinoma in approximately 70% of cases. The probability of experiencing any adverse oncological event (recurrence, progression or death) is less than 10% among patients who remain event‐free for 5 years.
Year:
2025
Objectives There are notable regional differences in the incidence and mortality of prostate cancer (PCa), whose underlying causes are arguably complex and multifactorial. In this review, we analysed the epidemiology, clinical characteristics, efficacy and safety of therapeutic drugs, prevalence of treatment and testing, and trends in PCa survival in Asian Urological Association member countries. Methods To investigate regional differences in incidence, mortality, and survival, we used the latest data from the GLOBOCAN 2022 edition, CONCORD‐3 study data, and the International Monetary Fund database. Results Asian men tend to present with more aggressive forms of PCa than their Caucasian counterparts. Paradoxically, survival outcomes are often better in Asian populations despite their more aggressive disease profiles. According to the GLOBOCAN 2022 data, PCa incidence is the highest in North America, Oceania, and Europe, but the lowest in incidence and mortality in Asian countries, despite varying significantly across these countries. Many developing Asian countries continue to experience rising mortality rates from PCa, largely due to limited access to PCa screening and disparities in healthcare infrastructure. While PCa treatments demonstrate comparable effectiveness in Asian populations to that in global trials, access to these therapies remains highly variable across the Asia–Pacific region, highlighting the need for access to improved healthcare policies and systems. In developing Asian nations, the 5‐year survival rate (5Y‐SR) is shown to be positively correlated with gross domestic product (GDP) per capita, suggesting that economic factors play a key determinant in PCa outcomes in these regions. Conclusions Our analysis reveals stark disparities between developed and developing Asian countries, particularly in mortality‐to‐incidence ratios, prostate‐specific antigen screening coverage, access to novel therapeutics, and reimbursement policies. Despite medical advances, economic status and health policy infrastructure remain key determinants of PCa outcomes in Asia. Moreover, our analysis of 5Y‐SR relative to GDP per capita underscores the colossal impact of the latter on PCa prognosis.
Year:
2025
Background A multicenter database was utilized to examine the current treatment landscape and clinical outcomes among patients with metastatic hormone‐sensitive prostate cancer (mHSPC) following approval of upfront androgen receptor signaling inhibitors (ARSIs). Methods We retrospectively analyzed patients with mHSPC who commenced treatment between February 2018 and June 2023. The Kaplan–Meier method was used to assess oncological outcomes, including time to castration‐resistant prostate cancer (CRPC), progression‐free survival 2 (PFS2, duration from initial treatment to tumor progression during second‐line treatment), cancer‐specific survival (CSS), and overall survival (OS). Cox regression analyses were performed to determine the impact of treatment choices on oncological outcomes. In addition, the incidence rate of adverse events was assessed. Results In total, 829 patients were analyzed; 42.5% received ARSIs with androgen deprivation therapy (ADT), 44.0% received combined androgen blockade (CAB), and 13.5% received ADT alone. Kaplan–Meier curves and multivariate Cox regression analyses indicated higher rates of CRPC and shorter PFS2 in patients treated with CAB versus ARSIs with ADT. By contrast, CSS and OS were not significantly different between the ARSI with ADT group and the CAB group. Grades 3–4 adverse events occurred in 1.9% of patients receiving CAB and 6.0% of those receiving ARSIs with ADT. Conclusions Initial treatment with ARSIs in combination with ADT resulted in a longer time to CRPC and longer PFS2 compared to CAB. Although CAB and ADT alone were associated with fewer adverse events, ARSIs with ADT should be considered a first‐line treatment option given its superior oncological outcomes.
Year:
2024
Background There is sparse evidence regarding optimal management and prognosticators for oncologic outcomes in patients with clinical node‐positive (cN+) upper tract urothelial carcinoma (UTUC). Methods We retrospectively analyzed the data from 105 UTUC patients with cN1‐2M0 between June 2010 and June 2022 at multiple institutions affiliated with our university. At the time of diagnosis, all patients received standard‐of‐care treatment including radical nephroureterectomy (RNU), chemotherapy, and/or palliative care. We employed a Cox regression model to analyze the prognostic importance of various factors on overall survival (OS). Results Of 105 patients, 54 (51%) underwent RNU, while 51 (49%) did not. RNU was likely to be selected in patients with younger and higher G8 score, resulting in better median OS in patients who underwent RNU than in those who did not (42 months vs. 15 months, p < 0.001). Multivariable analysis among the entire cohort revealed that low G8 score (≤14) (hazard ratio [HR]: 2.07, 95% confidence interval [CI]: 1.08–3.99), elevated pretreatment C‐reactive protein (CRP) (HR: 3.35, 95%CI: 1.63–6.90), and failure to perform RNU (HR: 2.16, 95%CI: 1.06–4.42) were independent prognostic factors for worse OS. In the subgroup analyses of cohorts who did not undergo RNU, elevated pretreatment CRP was the only independent prognostic factor for worse OS in cN+ UTUC patients. Conclusions RNU seems to be a reasonable treatment option in cN+ UTUC patients where applicable. Elevated pretreatment CRP appears to be a reliable prognosticator of worse OS and may be helpful in optimizing candidate selection for intensified treatment in this setting.
Year:
2024
Collaborators (9)
Jun Miki
Associate Professor
-
Francesco Soria
-
David D'Andrea
Associate Professor
-
Francesco Paolo Del Giudice
Sapienza University of Rome
Jeremy Yuen-Chun Teoh
The Chinese University of Hong Kong (CUHK)
Simone Albisinni
Université libre de Bruxelles
Andrea Mari
Assistant Professor
Institute of Experimental Medicine
Takahiro Kimura
Jikei University School of Medicine
Renate Pichler
Medical University of Innsbruck
Make your next move.
Prepare your application
Review drafts before you send them.